Telix Pharmaceuticals | TLX - Ebitda

Stock Price
14.76
Daily Change
0.12 0.82%
Monthly
15.31%
Yearly
-41.38%
Q2 Forecast
14.36

Telix Pharmaceuticals reported AUD18.42M in EBITDA for its fiscal semester ending in December of 2025.





Ebitda Change Date
Cochlear AUD 306.4M 13.5M Dec/2025
CSL USD 3.13B 1.17B Dec/2025
Integral Diagnostics AUD 46.27M 3.52M Jun/2024
Mayne Pharma AUD 20.9M 5.2M Jun/2025
Medical Developments International AUD 1.78M 3.78M Dec/2024
Mesoblast USD -20.3M 2.51M Dec/2025
Neuren Pharmaceuticals AUD 11.14M 165.56M Dec/2025
Pacific Edge NZD -13.97M 332K Sep/2024
Paradigm Biopharmaceuticals AUD -5.86M 3.79M Dec/2024
Polynovo AUD 3.89M 100K Dec/2025
PYC Therapeutics AUD -22.79M 1.5M Dec/2025
Ramsay Health Care AUD 1.12B 10.6M Dec/2025
ResMed USD 547.48M 27.46M Dec/2025
Sonic Healthcare AUD 839.07M 51.09M Dec/2024